To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

GSK Investigational Site, Shenyang

GSK Investigational Site, Shanghai

GSK Investigational Site, Hangzhou

GSK Investigational Site, Hangzhou

GSK Investigational Site, Taizhou

GSK Investigational Site, Jiangxi

GSK Investigational Site, Nanchang

GSK Investigational Site, Shenzhen

GSK Investigational Site, Jinjiang

GSK Investigational Site, Guangzhou

GSK Investigational Site, Guangzhou

GSK Investigational Site, Huizhou

GSK Investigational Site, Huizhou

GSK Investigational Site, Dongguan

GSK Investigational Site, Yinchuan

GSK Investigational Site, Beijing

GSK Investigational Site, Chengdu

GSK Investigational Site, Fuzhou

GSK Investigational Site, Gansu

GSK Investigational Site, Hefei

GSK Investigational Site, Mianyang

GSK Investigational Site, Panzhihua

GSK Investigational Site, Shenyang

GSK Investigational Site, Shenzhen

GSK Investigational Site, Tianjin

GSK Investigational Site, Weifang

GSK Investigational Site, Wuhan

GSK Investigational Site, Xianyang

GSK Investigational Site, Yiwu

GSK Investigational Site, Warsaw